1. Home
  2. CTNM vs FSBW Comparison

CTNM vs FSBW Comparison

Compare CTNM & FSBW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • FSBW
  • Stock Information
  • Founded
  • CTNM 2009
  • FSBW 1936
  • Country
  • CTNM United States
  • FSBW United States
  • Employees
  • CTNM N/A
  • FSBW N/A
  • Industry
  • CTNM
  • FSBW Banks
  • Sector
  • CTNM
  • FSBW Finance
  • Exchange
  • CTNM Nasdaq
  • FSBW Nasdaq
  • Market Cap
  • CTNM 328.1M
  • FSBW 301.1M
  • IPO Year
  • CTNM 2024
  • FSBW 2012
  • Fundamental
  • Price
  • CTNM $10.93
  • FSBW $39.67
  • Analyst Decision
  • CTNM Strong Buy
  • FSBW Hold
  • Analyst Count
  • CTNM 5
  • FSBW 1
  • Target Price
  • CTNM $20.40
  • FSBW $44.00
  • AVG Volume (30 Days)
  • CTNM 166.5K
  • FSBW 14.7K
  • Earning Date
  • CTNM 10-30-2025
  • FSBW 10-21-2025
  • Dividend Yield
  • CTNM N/A
  • FSBW 2.78%
  • EPS Growth
  • CTNM N/A
  • FSBW N/A
  • EPS
  • CTNM N/A
  • FSBW 4.09
  • Revenue
  • CTNM N/A
  • FSBW $140,954,000.00
  • Revenue This Year
  • CTNM N/A
  • FSBW $10.46
  • Revenue Next Year
  • CTNM N/A
  • FSBW $4.42
  • P/E Ratio
  • CTNM N/A
  • FSBW $9.86
  • Revenue Growth
  • CTNM N/A
  • FSBW 1.07
  • 52 Week Low
  • CTNM $3.35
  • FSBW $34.61
  • 52 Week High
  • CTNM $16.25
  • FSBW $48.05
  • Technical
  • Relative Strength Index (RSI)
  • CTNM 47.95
  • FSBW 57.73
  • Support Level
  • CTNM $10.46
  • FSBW $38.84
  • Resistance Level
  • CTNM $13.09
  • FSBW $39.70
  • Average True Range (ATR)
  • CTNM 0.98
  • FSBW 1.03
  • MACD
  • CTNM 0.08
  • FSBW 0.07
  • Stochastic Oscillator
  • CTNM 29.68
  • FSBW 78.58

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About FSBW FS Bancorp Inc.

FS Bancorp Inc is the holding company of 1st Security Bank, a diversified lender with a focus on the origination of commercial real estate, one-to-four-family, and home equity loans, consumer loans, including a variety of indirect home improvement (fixture secured loans), and marine loans, and commercial business loans. The company has two operating segments; The commercial and consumer banking segment provides diversified financial products and services to its commercial and consumer customers through Bank branches, automated teller machines, online banking platforms, mobile banking apps, and telephone banking; and The home lending segment originates one-to-four-family residential mortgage loans for sale in the secondary markets as well as loans held for investment.

Share on Social Networks: